Am J Transplant, Volume 18, Suppl 3 Archives - Page 198 of 211 - ATC Abstracts

2018 American Transplant Congress
Hypothermic Machine Perfusion Protects DCD Liver Graft through Metabolism of Xenobiotics by Cytochrome P450 Pathway
Q. Ye,^1,2 W. Liang,¹ Z. Zhong,¹ S. Ye,¹ B. Tang,¹ Q. Hu,¹ J. Liang,¹ Y. Wang.¹
¹Transplant Center of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan, China; ²The 3rd Xiangya Hospital of Central South Unversity, Changsha, China.
Background: Donation after cardiac death (DCD) is the mainly resource to relieve organ-transplantation shortage. Our previous research have confirmed that the function of DCD liver…
2018 American Transplant Congress
Origin and Traffic of Donor-Derived Extracellular Vesicles during Allo-Sensitization
F. Zeng,¹ W. Shufesky,¹ M. Yang,¹ Q. Liu,¹ A. Larregina,² A. Morelli.¹
¹T.E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA; ²Department of Dermatology, University of Pittsburgh, Pittsburgh, PA.
The idea that donor dendritic cells (DCs) transplanted with the grafts and mobilized to draining lymphoid tissues (dLTs) present donor MHC molecules to allo-reactive naïve…
2018 American Transplant Congress
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients
S. Jordan,¹ S. Bunnapradist,² J. Bromberg,³ A. Langone,⁴ D. Hiller,⁵ J. Yee,⁵ J. Sninsky,⁵ R. Woodward,⁵ A. Matas.⁶
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²UCLA, Los Angeles, CA; ³University of Maryland School of Medicine, Baltimore, MD; ⁴Vanerbilt University Medical Center, Nashville, TN; ⁵CareDx, Brisbane, CA; ⁶University of Minnesota School of Medicine, Minneapolis, MN.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) discriminates active rejection in kidney transplant patients. Donor-specific antibodies (DSA) to HLA antigens are associated with risk of antibody-mediated rejection…
2018 American Transplant Congress
Introduction of Direct Acting Antivirals for HCV: Fewer Kidney Discards but a Long Way to Go
T. Alhamad,¹ R. Thakkar,¹ D. Brennan,² J. Lappin,³ B. Kaplan,³ A. Malone,¹ V. Hicks,¹ J. Wellen,¹ K. Lentine.⁴
¹Washington University in St. Louis, St. Louis; ²Johns Hopkins University, Baltimore; ³Baylor Scott and White, Temple; ⁴Saint Louis University, St. Louis.
Organ shortage remains a great challenge facing the field of kidney transplantation. Donor hepatitis C virus positivity (DHCV+) is one of the highest ranking factors…
2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
R. George,¹ H. Sullivan,² R. Garro,¹ P. Winterberg,¹ B. Warshaw,¹ H. Gebel,² R. Bray.²
¹Pediatric Nephrology, Emory University & Children's Healthcare of Atlanta, Atlanta, GA; ²Dept. of Pathology, Emory Transplant Center, Emory University, Atlanta, GA.
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…
2018 American Transplant Congress
Evolving Trends in Demographic and Medical Characteristics of Liver Transplant Recipients
R. Rosenblatt,¹ N. Shen,¹ Z. Tafesh,¹ B. Fortune,¹ K. Halazun,¹ A. Jesudian.¹
¹Medicine/Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY; ²Surgery, Weill Cornell Medicine, New York, NY.
IntroductionThe characteristics of liver transplant (LT) recipients have evolved over time as centers adapt to allocation policy changes and the shifting demographics of the US…
2018 American Transplant Congress
Comparison of Induction and Maintenance Immunosuppression Regimens in Intestinal and Multivisceral Transplantation: An Analysis of the UNOS Registry
S. Nagai,¹ M. Rizzari,¹ Y. Muszkat,² K. Collins,¹ A. Yoshida,¹ S-.M. Jafri,² M. Abouljoud.¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI; ²Gastroenterology, Henry Ford Hospital, Detroit, MI.
Aim: Induction and maintenance immunosuppression regimens in intestinal transplant widely vary among centers. The aim of this study was to investigate an association between immunosuppression…
2018 American Transplant Congress
Multicentre Epidemiological Study on Prevalence of Recurrent Glomerular Disease Post-Transplantation in the United Kingdom
R. Aguiar.
On Behalf of NIHR Health Informatics Collaborative (HIC)- Transplantation Theme, London, United Kingdom.
Introduction: Primary glomerulonephritidies (GN) can recur in the renal allograft and are possibly associated with poorer allograft outcome. The prevalence of recurrence varies widely and…
2018 American Transplant Congress
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry
S. Sanoff,¹ K. Ravindra,¹ W. Irish.^1,2
¹Duke University Medical Center, Durham, NC; ²CTI Consulting, Raleigh, NC.
Introduction:Belatacept (BEL) was FDA approved for Kidney Transplantation (KTx) June 2011. It has largely been evaluated in two controlled trials (N Engl J Med 2016;374:333-43).…
2018 American Transplant Congress
Aggressive Immunosuppression Minimization Shortens BK Viremia, Does Not Improve Outcome, but Increases the Risk of De Novo Donor Specific Antibodies in Kidney Recipients
A. Devresse,^1,2 C. Tinel,¹ A. Vermorel,¹ R. Snanoudj,¹ L. Morin,¹ V. Avettand-Fenoel,³ L. Amrouche,¹ A. Scemla,¹ J. Zuber,¹ C. Legendre,¹ M. Rabant,⁴ D. Anglicheau.¹
¹Nephrology and Kidney Transplantation, Necker Hospital, Paris, France; ²Nephrology, University Hosputal Saint-Luc, Brussels, Belgium; ³Virology, Necker Hospital, Paris, France; ⁴Pathology, Necker Hospital, Paris, France.
Background: Immunosuppression (IS) minimization is the gold-standard treatment of BK virus (BKV) viremia in kidney transplant recipients (KTRs). However, the optimal approach to IS reduction…